B+
Bull case
20%
Probability
Target price
$3.00
+27.7% vs current
CDIO
Cardio DiagnosticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.90
-19.1% vs current
B-
Bear case
30%
Probability
Target price
$0.70
-70.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+23.2
Score
AI commentary
Coverage is thin and mostly filing-led. The latest 10-Q and 10-K evidence keeps burn, dilution, reimbursement, and CLIA execution as the main issues; there is no analyst revision signal in the packet, and the recent news flow is mostly promotional investor-outreach content rather than a new fundamental step-change. The $1.803 anchor sits below the sparse $2.00 median target, but that target is too thinly sourced to carry much weight. The available peers are broad medtech scale references or microcap capital-markets comparators, so this should remain a cautious monitoring view rather than a standard-conviction peer-relative thesis.
RankAlpha Sentiment Codex - 2026-05-29
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-05-15eventQ1 2026 10-Q keeps cash burn and dilution front and centerMedium impact
The 2026-05-15 10-Q showed the business still generating only de minimis product-test sales, with a net loss, cash of $7.08M, and continued ATM issuance; that keeps burn and dilution as the primary near-term facts [#10-Q-2026-05-15].
2026-06-30catalystReimbursement and billing traction in Q2 2026 remains the key gating itemHigh impact
Management said in the 2025 10-K it was still pursuing Medicare coverage and expected to be able to submit commercial claims out-of-network beginning in Q2 2026; tangible billing or coverage progress would matter more than promotional awareness updates [#10-K-2026-03-13].
2026-12-31catalystFinancing access, CLIA lab scale, and India partnership conversion must turn into repeatable reimbursable volumeHigh impact
The longer-horizon thesis still depends on converting financing access, CLIA lab scale, and the February 2026 India partnership update into repeatable reimbursable test volume; until that happens, the equity remains a financing-and-execution story rather than a scaled commercial one [#10-K-2026-03-13] [#8-K-2026-02-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-29 • Updated nightlySource: Internal modelMethodology